Risks of reformulation: French patients complain after Merck modifies levothyroxine pills

BMJ 2018; 360 doi: (Published 23 February 2018) Cite this as: BMJ 2018;360:k920

The details of the lawsuits described in the box in this article (BMJ 2018;360:k714, doi:10.1136/bmj.k714) were incorrect. Vivre sans thyroîde has asked the law firm MySMARTcab to seek an “emergency expertise procedure,” which will be heard in Paris on 23 February. MySMARTcab has already filed the civil claim for compensation against Merck. The case will be heard in Lyon on 1 October 2018.

View Abstract